Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07417566Phase 1Recruiting

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

Role: lead

NCT07071090Phase 1Recruiting

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Role: lead

NCT06873555Phase 1Recruiting

A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

Role: lead

NCT06864182Phase 1Completed

Relative Bioavailability Study of CX2101A for the Treatment of COVID-19

Role: lead

NCT06873542Phase 1Completed

A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors

Role: lead

NCT06860282Phase 1Completed

A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects

Role: lead

All 6 trials loaded